Not Signed In -
Adrenal Gland Disorders |
Adrenal Disease; Disorder |
Clinical Trial: Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
This study is no longer recruiting patients.
Purpose
The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Opioid-Related Disorders Substance-Related Disorders | Drug: Buprenorphine | Phase II |
MedlinePlus related topics: Drug Abuse; Prescription Drug Abuse
Study Type: Interventional
Study Design: Treatment, Uncontrolled
Official Title: Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot
Further Study Details:
Expected Total Enrollment: 21
Study start: December 1995
Eligibility
Ages Eligible for Study: 21 Years - 55 Years, Genders Eligible for Study: Both
Criteria
Please contact site for information.
Location Information
Connecticut
APT Residential Services Division, New Haven, Connecticut, 06519, United States
Study chairs or principal investigators
Richard Schottenfeld, M.D., Principal Investigator, Yale University
More Information
Study ID Numbers: NIDA-09803-1; R01-09803-1
Record last reviewed: December 1995
Last Updated: March 17, 2005
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000318
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: December 1995
Last Updated: March 17, 2005
Record first received: September 20, 1999
ClinicalTrials.gov Identifier: NCT00000318
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- AACE Physician Finder (American Association of Clinical Endocrinologists)
- ACTH (Adrenocorticotropic Hormone) Test (American Association for Clinical Chemistry)
email this page
print this page
bookmark this page
feedback on this page
